CSF‐plasma biomarker profiles from BioFINDER MCI patients using the same technology

Technological advancements have made it possible to translate changes in cerebrospinal fluid (CSF) into promising plasma biomarkers, such as the amyloid β ratio (Aβ42/Aβ40) and phosphorylated tau (p‐tau), but comparing CSF and plasma levels were often based on different technologies. Combining biomarkers have demonstrated a superior performance of the ratio of p‐tau over Aβ42 to discriminate Aβ‐positive (Aβ+) and Aβ‐negative (Aβ‐) groups in CSF, especially using automated immunoassay platforms, but has not yet been studied in plasma.